Infliximab Biosimilars Insights 2020 | DelveInsight

 DelveInsight launched a report titled, “Infliximab Biosimilar Insights, 2020,” which provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape.

The report covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

It further highlights the inactive pipeline products in this space. 

Geography Covered

·         Global coverage

View full report: https://www.delveinsight.com/report-store/infliximab-biosimilars-insight

Infliximab Overview

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease.

Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades.

By binding to both the soluble subunit and the membrane-bound precursor of TNF-α 1, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α 1.

Request for sample pages of the report: https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight

Infliximab Biosimilars: Drugs Chapters

1.    Infliximab Biosimilars: Marketed Drugs

·  Inflectra: Celltrion/Pfizer

·  Renflexis: Merck

Crohn’s Disease (moderately to severely active): Can reduce signs and symptoms and induce and maintain remission in adult patients with moderately to severely active Crohn’s disease who haven't responded well to other therapies

Pediatric Crohn’s Disease (moderately to severely active): Can reduce signs and symptoms and induce and maintain remission in children (ages 6–17) with moderately to severely active Crohn's disease who haven't responded well to other therapies

Ulcerative Colitis (moderately to severely active): Can reduce signs and symptoms, induce and maintain remission, promote intestinal healing, and reduce or stop the need for steroids in adult patients with moderately to severely active ulcerative colitis who haven't responded well to other therapies

Pediatric Ulcerative Colitis (moderately to severely active): Can reduce signs and symptoms, induce and maintain remission, promote intestinal healing, and reduce or stop the need for steroids in children (ages 6–17) with moderately to severely active ulcerative colitis who haven't responded well to other therapies

2.    Infliximab Biosimilars: Emerging Drugs

·  BCD 055: Biocad

·  CT-P17: Celltrion

Read more about Infliximab Biosimilars @https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight

Key Pharma players involved:

·  Sandoz

·  Samsung Bioepis

·  Merck

·  Nichiiko Pharmaceutical

·  Aprogen

·  And others.

Emerging therapies:

·  Zessly

·  Renflexis/SB2

·  SB2

·  Infimab

·  Ixifi

·  And others.

Download full report: https://www.delveinsight.com/report-store/infliximab-biosimilars-insight

 

Comments

Post a Comment

Popular posts from this blog

Cyclin-dependent kinase

Image
Cyclin-dependent kinase overview Cyclin-dependent kinases (CDKs) belong to a protein serine/threonine kinases whose activity depends on association with a noncatalytic regulatory subunit called a cyclin. Cyclin-dependent kinases inhibitors are vital for progression through the cell cycle and proliferation. The genes that encode CDKs were initially identified in screens for conditional mutants of Saccharomyces cerevisiae which reversibly arrested at characteristic points in the cell cycle upon transfer to the restrictive conditions. Cyclins were initially named for their periodic accumulation and degradation (cycling) through the early cell cycles of fertilized sea urchin eggs. This research identified a ubiquitous cell cycle engine responsible for coordinating cell growth, DNA replication, and mitosis in the orderly fashion required to ensure the viability of progeny cells. How Do Cyclin-dependent kinases regulate Cell Cycle? All eukaryotes have a various cyclins,
Read more

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Smoking Cessation Market Research Report 2030 | Smoking Cessation Market

Image
Smoking Cessation   is a process of discontinuing tobacco smoking. Cigarette smoking is the leading cause of chronic obstructive pulmonary disease, and quitting smoking is the most effective way to slow down the progression of the disease. Tobacco use can potentially lead to tobacco or nicotine addiction, as well as significant health consequences, according to the CDC. It has the potential to significantly lower the risk of smoking-related diseases. Nicotine is addictive, but no effective medications or behavioral therapies are available to help people overcome it. Counseling, nicotine replacement, and bupropion have all been shown to aid in smoking cessation in several studies. Smoking Cessation Sign and Symptoms The most significant barrier to quitting smoking is nicotine addiction. Smokers who try to stop often experience cravings for cigarettes, mood swings, insomnia, constipation, increased hunger, anxiety, and other nicotine withdrawal symptoms. Tobacco quitting lowers the chanc
Read more